Health Care [ 3/12 ] | Pharmaceuticals [ 18/75 ]
NASDAQ | Common Stock
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI.
It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines.
The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases.
It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia.
It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications.
The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 10, 26 | 0.00 Decreased by -100.00% | 1.06 Decreased by -100.00% |
| Nov 6, 25 | 1.19 Increased by +14.42% | 1.14 Increased by +4.39% |
| Jul 29, 25 | 0.79 Decreased by -20.20% | 0.88 Decreased by -10.23% |
| Apr 29, 25 | 1.25 Increased by +21.36% | 1.12 Increased by +11.61% |
| Feb 6, 25 | 1.05 Increased by +43.84% | 1.04 Increased by +0.96% |
| Nov 12, 24 | 1.04 Increased by +19.54% | 1.03 Increased by +0.97% |
| Jul 25, 24 | 0.99 Decreased by -8.33% | 1.20 Decreased by -17.50% |
| Apr 25, 24 | 1.03 Increased by +7.29% | 1.22 Decreased by -15.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 15.19 B Increased by +11.99% | 2.53 B Increased by +77.26% | Increased by +16.67% Increased by +58.28% |
| Jun 30, 25 | 14.46 B Increased by +11.74% | 2.45 B Increased by +27.14% | Increased by +16.95% Increased by +13.78% |
| Mar 31, 25 | 13.59 B Increased by +7.17% | 2.92 B Increased by +33.82% | Increased by +21.46% Increased by +24.87% |
| Dec 31, 24 | 14.89 B Increased by +23.84% | 1.50 B Increased by +56.25% | Increased by +10.07% Increased by +26.17% |
| Sep 30, 24 | 13.56 B Increased by +18.04% | 1.43 B Increased by +4.00% | Increased by +10.53% Decreased by -11.89% |
| Jun 30, 24 | 12.94 B Increased by +13.33% | 1.93 B Increased by +6.00% | Increased by +14.89% Decreased by -6.47% |
| Mar 31, 24 | 12.68 B Increased by +16.55% | 2.18 B Increased by +20.85% | Increased by +17.19% Increased by +3.70% |
| Dec 31, 23 | 12.02 B Increased by +7.29% | 960.00 M Increased by +6.55% | Increased by +7.98% Decreased by -0.69% |